Eleanor A. Fallon

Eleanor A. Fallon

Auto-generated profile, based on publicly available information

Eleanor A. Fallon

Brown University/Rhode Island Hospital, Providence, RI

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
TRTodd K. Rosengart
Todd K. Rosengart
JRJamie L. Romeiser
Jamie L. Romeiser
LWLauren J. White
Lauren J. White
AFAshley Fratello
Ashley Fratello
EFEleanor Fallon
Eleanor Fallon
ASAnnie Laurie Shroyer
Annie Laurie Shroyer

29 January 2020 in American Journal of Physiology-Lung Cellular and Molecular Physiology
Verified
Journal Article
Closed access
PDF file
SXShumin Xu
Shumin Xu
QYQian Yang
Qian Yang
JBJianwen Bai
Jianwen Bai
TTTianzhu Tao
Tianzhu Tao
LTLunxian Tang
Lunxian Tang
AAAlfred Ayala
Alfred Ayala
This study sets out to establish the comparative contribution of PD-L1 expression by pulmonary endothelial cells (ECs) and/or epithelial cells (EpiCs) to the development of indirect acute lung injury (iALI) by taking advantage of the observation that treatment with naked siRNA by intra-tracheal (I.T.) delivery in mice primarily effects lung EpiCs, but not lung ECs; while intravenous (I.V.) delivery of liposomal encapsulated siRNA largely targets vascular ECs including the lung, but not pulmonary EpiCs. We showed that, using a mouse model of iALI (induced by hemorrhage followed by septic challenge [Hem-CLP]), PD-L1 expression on pulmonary ECs or EpiCs was significantly up-regulated in the iALI mice at 24h post-septic insult. After documenting the selective ability of I.T. vs. I.V. delivery of PD-L1siRNA to inhibit PD-L1 expression on EpiCs vs. ECs, respectively, we observed that the iALI-induced elevation of cytokine/chemokine levels (in the broncho-alveolar lavage fluid, lung lysates or plasma), lung MPO and caspase-3 activities could largely only be inhibited by I.V., but not I.T. delivery of PD-L1 siRNA. Moreover, I.V., but not I.T., delivery led to a preservation of normal tissue architecture, lessened pulmonary edema and reduced neutrophils influx induced by iALI. In addition, in vitro mouse endothelial cell line studies showed that PD-L1 gene knockdown by siRNA or knockout by CRISPR/Cas9-mediated gene manipulation reduced monolayer permeability and maintained tight junction protein levels upon recombinant IFN-g stimulation. Together, these data imply a critical role for pulmonary vascular ECs in mediating PD-1:PD-L1 driven pathological changes resulting from systemic stimuli such as Hem-CLP

1 May 2017 in Surgery
Verified
Journal Article
Closed access
WYWhitney A. Young
Whitney A. Young
EFEleanor A. Fallon
Eleanor A. Fallon
DHDaithi S. Heffernan
Daithi S. Heffernan
PEPhilip A. Efron
Philip A. Efron
WCWilliam G. Cioffi
William G. Cioffi
AAAlfred Ayala
Alfred Ayala

20 November 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
EFEleanor A. Fallon
Eleanor A. Fallon
TCTristen T. Chun
Tristen T. Chun
WYWhitney A. Young
Whitney A. Young
CGChyna Gray
Chyna Gray
AAAlfred Ayala
Alfred Ayala
DHDaithi S. Heffernan
Daithi S. Heffernan
We have shown that invariant natural killer T (iNKT) cells mediate sepsis-induced end-organ changes and immune responses, including macrophage bacterial phagocytosis, a finding regulated by the check point protein program cell death receptor-1 (PD-1). Furthermore, PD-1 mediates mortality in both adult and neonatal murine sepsis as well as in surgical patients. Given our previous findings, we hypothesize that iNKT cells will also modulate neonatal sepsis survival, and that this effect is regulated in part through PD-1. We utilized a polymicrobial intra-peritoneal cecal slurry (CS) sepsis model in wild type (WT), iNKT−/− or PD-1−/− 5–7 day old neonatal pups. Typically, tissues were harvested at 24 h for various bioassays/histology and, in some cases, survival was assessed for up to 7 days. Interestingly, similar to what we recently reported for PD-1−/− mice following CS, iNKT−/−-deficient animals exhibit a markedly improved survival vs. WT. Histologically, minor alterations in liver architectural, which were noted in WT pups, were attenuated in both iNKT−/− and PD-1−/− pups. Following CS, PECAM-1 expression was unchanged in the WT pups but increased in both iNKT−/− and PD-1−/− pups. In WT, following CS the emergence of a Ly6Clow subpopulation was noted among the influxed peritoneal macrophage population. Conversely, within iNKT−/− pups, there were fewer peritoneal macrophages and a greater percentage of Ly6Chigh macrophages. We show not only a key role for iNKT cells in affecting end-organ damage as well as alterations in phagocytes phenotypes in neonatal sepsis but that this iNKT cell mediated effect is driven by the central checkpoint protein PD-1.

14 October 2022 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
CZChristopher Zoppo
Christopher Zoppo
DVDaniel Alvarez Valero
Daniel Alvarez Valero
VMVenkatesh Arumugam Murugan
Venkatesh Arumugam Murugan
APAlex Pavidapha
Alex Pavidapha
JFJulie Flahive
Julie Flahive
AHAaron Harman
Aaron Harman

1 January 2019 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Open access
ARAnne-Lise Rossi
Anne-Lise Rossi
MLMarilyn Le
Marilyn Le
CCChun-Shiang Chung
Chun-Shiang Chung
YCYaping Chen
Yaping Chen
EFEleanor A. Fallon
Eleanor A. Fallon
AAAlfred Ayala
Alfred Ayala
The liver is an organ that, when dysfunctional in a septic patient, is strongly associated with morbidity and mortality. Understanding the pathophysiology of liver failure during sepsis may lead to improved diagnostics and potential therapeutic targets. Historically, programmed cell death receptor (PD) ligand 1 (PD-L1) has been considered the primary ligand for its checkpoint molecule counterpart, PD-1, with PD-L2 rarely in the immunopathological spotlight. PD-1 and PD-L1 contribute to liver dysfunction in a murine cecal ligation and puncture (CLP) model of sepsis, but virtually nothing is known about PD-L2’s role in sepsis. Therefore, our central hypothesis was that sepsis-induced changes in hepatic PD-L2 expression contributed to worsened liver function and, subsequently, more pronounced morbidity and mortality. We found that although PD-L1 gene deficiency attenuated the hepatic dysfunction seen in wild-type mice after CLP, the loss of PD-L2 appeared to actually worsen indices of liver function along with a trend toward higher liver tissue vascular permeability. Conversely, some protective effects of PD-L2 gene deletion were noted, such as reduced liver/peritoneal bacterial load and reduced IL-6, IL-10, and macrophage inflammatory protein 2 levels following CLP. These diverse actions, as well as the unique expression pattern of PD-L2, may explain why no overt survival advantage could be witnessed in the septic PD-L2−/− mice. Taken together, these data suggest that although PD-L2 has some selective effects on the hepatic response seen in the septic mouse, these factors are not sufficient to alter septic mortality in this adult murine model. NEW & NOTEWORTHY Our study shows not only that ligands of the checkpoint protein PD-1 respond inversely to a stressor such as septic challenge (PD-L2 declines, whereas PD-L1 rises) but also that aspects of liver dysfunction increase in septic mice lacking the PD-L2 gene. Furthermore, these differences in PD-L2 gene-deficient animals culminated in the abrogation of the survival advantage seen in the septic PD-L1-knockout mice, suggesting that PD-L2 may have roles beyond a simple immune tolerogen.